Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File Photo

BEIJING, July 21 (Reuters) – Sinopharm’s COVID-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.

Antibody levels in people receiving Sinopharm’s BBIBP-CorV vaccine had a 1.38-fold reduction to the Delta variant versus an older version of the coronavirus first identified in Wuhan, a lab study based on samples from people in Sri Lanka showed. https://bit.ly/3hTjzJt

The study was conducted by

Read More At Article Source | Article Attribution